Orforglipron improves glycemic control and weight in early type 2 diabetes.

The phase 3 ACHIEVE-1 trial randomized 559 patients with early T2D, mean baseline HbA1c 8.0%, over 40 weeks. 

Key results: 

• Final HbA1c: 6.7% (3 mg), 6.4% (12 mg), 6.5% (36 mg) vs 7.8% placebo. 
• ≤6.5% HbA1c achieved in up to 66% vs 14–28% placebo. 
• ≥5% weight loss in 45–64% vs 19% placebo. 
• GI adverse events mild/moderate; low discontinuation (4.4–7.8%). No hepatic/pancreatic signals. 

Clinical context: As a non-peptide oral GLP-1 RA, orforglipron expands access to incretin-based therapies. Robust effects on HbA1c and weight strengthen its potential for patients unwilling or unable to use injectables. 

#Orforglipron #GLP1RAOral #Type2Diabetes #EASD2025 

Editorial note: This content was developed with the support of artificial intelligence technologies to optimize the writing and structuring of the information. All material was carefully reviewed, validated, and supplemented by human experts prior to publication, ensuring scientific accuracy and adherence to good editorial practices. 

Referências: 

Ludwig L, Thomas M, Eyde S, et al. Orforglipron monotherapy in early type 2 diabetes: efficacy and safety results from the ACHIEVE-1 trial. Diabetologia. 2025;68(Suppl 1):S—S. Abstract LBA SO02.